The Puget Sound Oncology Consortium (PSOC) has been a funded member of the Southwest Oncology Group (SWOG) since 1976. A multi-modality approach is utilized which includes: Pathology, Surgery, Chemotherapy, Radiation Therapy, Biological Response Modifier Therapy and Quality of Life evaluations for the aim of improving cancer care. Overall objectives are prolongation of life, increased quality of life, decreased toxicities, prolonged disease free survival, improvement in techniques of screening, early detection and prevention of cancer and the rapid transfer of innovative therapies from the laboratory to the clinic. PSOC is one of the largest SWOG member groups and altogether comprises a network of 27 hospitals and medical centers throughout the Pacific Northwest (Alaska, California, Montana, Oregon, and Washington). The scientific agenda of PSOC is determined by disease-specific committees who have contributed eight pilot studies to SWOG in the past grant period. PSOC has 22 investigators who coordinate or co-coordinate 26 studies and has 12 members who hold primary or contributing authorship in 42 published reports of SWOG studies. PSOC supports a urological cancer outreach program (UCOP) as well as five prostate cancer prevention trial (PCPT) sites. PSOC ranks number one in follow- up with a total caseload of 1,245 patients and averages an annual accrual of approximately 170 patients. The Prostate Cancer Prevention Trial has accrued 800 patients and the UCOP program has accrued 53 patients in this past grant period. PSOC maintains autologous and allogeneic bone marrow transplant programs as well as an active stem cell transplant program. Cytogenetics laboratories of SHMC and the UWMC are certified as submitting and reference laboratories. The Clinical Practices Committee formed by Saul E. Rivkin, MD, is evaluating resource utilization and cost effectiveness issues for patients receiving treatment on research protocols. Membership has steadily increased in the past grant period with the addition of three new CGOP affiliates and a total of 54 new members over the last five years. PSOC members are active in scientific and administrative activities and are dedicated to support the goals of the Southwest Oncology Group.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA020319-23
Application #
2856192
Study Section
Subcommittee G - Education (NCI)
Program Officer
Mooney, Margaret M
Project Start
1978-01-01
Project End
2002-12-31
Budget Start
1999-01-01
Budget End
1999-12-31
Support Year
23
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Swedish Medical Center, First Hill
Department
Type
DUNS #
City
Seattle
State
WA
Country
United States
Zip Code
98122
Samlowski, Wolfram E; Moon, James; Witter, Merle et al. (2017) High frequency of brain metastases after adjuvant therapy for high-risk melanoma. Cancer Med 6:2576-2585
Sala Torra, Olga; Othus, Megan; Williamson, David W et al. (2017) Next-Generation Sequencing in Adult B Cell Acute Lymphoblastic Leukemia Patients. Biol Blood Marrow Transplant 23:691-696
Haas, Naomi B; Manola, Judith; Uzzo, Robert G et al. (2016) Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet 387:2008-16
Othus, M; Mukherjee, S; Sekeres, M A et al. (2016) Prediction of CR following a second course of '7+3' in patients with newly diagnosed acute myeloid leukemia not in CR after a first course. Leukemia 30:1779-80
Lucas, David M; Ruppert, Amy S; Lozanski, Gerard et al. (2015) Cytogenetic prioritization with inclusion of molecular markers predicts outcome in previously untreated patients with chronic lymphocytic leukemia treated with fludarabine or fludarabine plus cyclophosphamide: a long-term follow-up study of the US intergr Leuk Lymphoma 56:3031-7
Blumenthal, Deborah T; Rankin, Cathryn; Stelzer, Keith J et al. (2015) A Phase III study of radiation therapy (RT) and O?-benzylguanine + BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001. Int J Clin Oncol 20:650-8
Othus, Megan; Appelbaum, Frederick R; Petersdorf, Stephen H et al. (2015) Fate of patients with newly diagnosed acute myeloid leukemia who fail primary induction therapy. Biol Blood Marrow Transplant 21:559-64
Ou, Sai-Hong Ignatius; Moon, James; Garland, Linda L et al. (2015) SWOG S0722: phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM). J Thorac Oncol 10:387-91
Budd, George T; Barlow, William E; Moore, Halle C F et al. (2015) SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol 33:58-64
Mir, Muhammad A; Maurer, Matthew J; Ziesmer, Steven C et al. (2015) Elevated serum levels of IL-2R, IL-1RA, and CXCL9 are associated with a poor prognosis in follicular lymphoma. Blood 125:992-8

Showing the most recent 10 out of 301 publications